Trojan Horse

Hep c was always just about safety and it was the most advanced clinically to take to the US to facilitate a Nasdaq listing.

The real deal was Hep B all along but they had to wait for prices to fall to lowest levels for the mother of all moonshots fuelled by the deepest capital markets in the world.

This is it boys. A 100-hundred bagger waiting for the spark. A delayed US Fed reserve interest rate rise ould just be what the Biotech bull run needs to resume its upward trajectory with the smallest companies flung into the stratosphere.

Good luck to all holders.